



Procter & Gamble Hygiene  
and Health Care Limited  
CIN: L24239MH1964PLC012971  
Registered Office:  
P&G Plaza  
Cardinal Gracias Road, Chakala  
Andheri (E), Mumbai 400 099  
Tel: (91-22) 2826 6000  
Fax: (91-22) 2826 7303  
www.pg.com/en\_IN

December 3, 2016

To,  
The Corporate Relations Department  
The BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400001

**Ref:- Scrip Code:- 500459**

Dear Sir / Madam,

**Sub: Unaudited Financial Results for the quarter ended September 30, 2016**

We are pleased to inform you that at a meeting of the Board of Directors of the Company held today, the Unaudited Financial Results for the quarter ended September 30, 2016 were approved.

We are enclosing herewith the following:


- a. Unaudited Financial Results for the quarter ended September 30, 2016
- b. Press Release
- c. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended September 30, 2016 furnished by Statutory Auditors of the Company.

Kindly take the same on record and oblige.

Thanking you,

Yours faithfully,

*For Procter & Gamble Hygiene and Health Care Limited*

  
*Preeti Bishnoi*  
Company Secretary

Encl: As Above



Procter & Gamble Hygiene  
and Health Care Limited  
CIN : L24239MH1964PLC012971  
Registered Office  
P&G Plaza  
Cardinal Gracias Road, Chakala  
Andheri (E), Mumbai 400 099  
(91 - 22) 2826 6000 phone  
(91 - 22) 2826 7303 fax  
www.pg.com/en\_IN

Part I

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30<sup>th</sup> SEPTEMBER 2016

₹ in Lakhs

Particulars	(1)	(2)	(3)	(4)
	Three Months Ended 30 <sup>th</sup> September 2016 (Unaudited)	Preceding Three Months Ended 30 <sup>th</sup> June 2016 (Unaudited)	Corresponding Three Months Ended 30 <sup>th</sup> September 2015 (Unaudited)	Previous Year Ended 30 <sup>th</sup> June 2016 (Unaudited)
<b>1 Income from operations</b>				
(a) Gross Sales / Income from operations	62198	56111	55300	234650
(b) Other operating income	52	118	43	265
<b>Total income from operations</b>	<b>62250</b>	<b>56229</b>	<b>55343</b>	<b>234915</b>
<b>2 Expenses</b>				
a) Cost of raw and packing materials consumed	13589	14632	14179	56198
b) Purchase of stock-in-trade	10492	5670	9608	33350
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	957	(1867)	(2085)	(1071)
d) Excise duty	2208	2871	1472	7376
e) Employee benefits expense	3768	2986	3344	11786
f) Depreciation and amortisation expense	1271	1241	1271	5167
g) Advertising & sales promotion expenses	6193	4055	5099	20057
h) Other expenses	9927	12005	14030	46687
<b>Total expenses</b>	<b>48405</b>	<b>41593</b>	<b>46918</b>	<b>179550</b>
<b>3 Profit from operations before other income and finance costs (1-2)</b>	<b>13845</b>	<b>14636</b>	<b>8425</b>	<b>55365</b>
4 Other income	2251	2218	2121	8761
<b>5 Profit from ordinary activities before finance costs (3+4)</b>	<b>16096</b>	<b>16854</b>	<b>10546</b>	<b>64126</b>
6 Finance costs	43	83	165	600
<b>7 Profit from ordinary activities before tax (5-6)</b>	<b>16053</b>	<b>16771</b>	<b>10381</b>	<b>63526</b>
8 Tax expense	5609	5851	3425	21292
<b>9 Net profit for the period (7-8)</b>	<b>10444</b>	<b>10920</b>	<b>6956</b>	<b>42234</b>
10 Other comprehensive income (net of tax)	(72)	(29)	(29)	(116)
<b>11 Total Comprehensive income (after tax) (9+10)</b>	<b>10372</b>	<b>10891</b>	<b>6927</b>	<b>42118</b>
12 Paid-up equity share capital (Face Value ₹ 10 per equity share)	3246	3246	3246	3246
13 Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year				161932
<b>14 Earnings per Share (Face value of ₹ 10 per equity share) (not annualised) :</b>				
a) Basic	32.17	33.64	21.43	130.11
b) Diluted	32.17	33.64	21.43	130.11
<b>See accompanying notes to the financial results</b>				



Procter & Gamble Hygiene  
and Health Care Limited  
CIN : L24239MH1964PLC012971  
Registered Office  
P&G Plaza  
Cardinal Gracias Road, Chakala  
Andheri (E), Mumbai 400 099  
(91 - 22) 2826 6000 phone  
(91 - 22) 2826 7303 fax  
www.pg.com/en\_IN/

**Notes :**

- The above results were approved by the Board of Directors of the Company at the Board Meeting held on 3rd December, 2016. In compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a limited review of the above results has been carried out by the Statutory Auditors.
- The financial results of the Company have been prepared in accordance with Indian Accounting Standard (IND AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) Rules, 2016. The Company adopted IND AS from 1st July, 2016, and accordingly, these financial results (including for all the periods presented) have been prepared in accordance with the recognition and measurement principles in IND AS 34 - Interim Financial Reporting, prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India. The date of transition to IND AS is July 1, 2015. The impact of the transition has been accounted for in opening reserves and the comparable periods / preceding year end have been restated accordingly.
- The figures for the preceding three months ended 30th June, 2016 are the balancing figures between the unaudited figures in respect of the full financial year ended 30th June, 2016 and the year to date figures upto the third quarter of that financial year.
- A reconciliation of the financial results to those reported under Previous Generally Accepted Accounting Principles (GAAP) are summarise as follows:

(₹ in Lakhs)

Particulars	Notes	Three Months Ended 30 <sup>th</sup> June 2016	Three Months Ended 30 <sup>th</sup> Sept 2015	Year Ended 30 <sup>th</sup> June 2016
<b>Profit after tax as reported under previous GAAP</b>		<b>10 940</b>	<b>6 978</b>	<b>42 318</b>
1) Change in accounting of group share based payment arrangements which were erstwhile accounted as expense when re-charged by the group, now accounted as equity settled scheme over the vesting period	(a)	( 75)	( 77)	( 306)
2) Reclassification of actuarial gains / (losses), arising in respect of defined benefit plans		45	44	178
3) Deferred Tax Impact		10	11	44
<b>Profit after tax as reported under IND AS</b>		<b>10 920</b>	<b>6 956</b>	<b>42 234</b>
Other comprehensive income (net of tax)		( 29)	( 29)	( 116)
<b>Total Comprehensive Income as reported under IND AS</b>		<b>10 891</b>	<b>6 927</b>	<b>42 118</b>

(a) Under IND AS, the cost of P&G USA Stock Options is recognised based on the fair value of the options as on the grant date. In terms of the exemptions, the fair value of unvested options as at the date of transition have been accounted for as part of reserves. The fair value of options vesting after the transition date have been recognised in profit or loss.

- The Company has identified Health and Hygiene Products as its only primary reportable segment in accordance with the requirements of IND AS 108 - Operating Segments. Accordingly no separate segment information has been provided

Place : Mumbai  
Date : 3<sup>rd</sup> December, 2016

For and on behalf of the Board of Directors of  
Procter & Gamble Hygiene and Health Care Limited

*Al Rajwani*

Al Rajwani  
Managing Director





**Procter & Gamble Hygiene  
and Health Care Limited**  
CIN: L24239MH1964PLC012971  
Registered Office:  
P&G Plaza  
Cardinal Gracias Road, Chakala  
Andheri (E), Mumbai 400 099  
Tel: (91-22) 2826 6000  
Fax: (91-22) 2826 7303  
[www.pg.com/en\\_IN](http://www.pg.com/en_IN)

**Procter & Gamble Hygiene and Health Care Ltd. continues to deliver Sustained Growth**

*Net Sales up 12%; PAT up 50% for quarter ended September 30, 2016*

**Mumbai, December 3, 2016** – Procter & Gamble Hygiene and Health Care Ltd. (PGHHCL) announced today its financial results for the quarter ended September 30, 2016. The Company delivered total net sales of Rs. 622 crores, up 12% versus year ago. Profit After Tax (PAT) was at Rs. 104 crores, up 50% versus year ago. The company continues to focus on productivity and cost efficiency.

Both the Feminine Care and Health Care businesses continued to deliver strong sales growth in a competitive market environment behind superior value propositions, strength of product portfolio and improved in-store execution.

**About Procter & Gamble Hygiene and Health Care Ltd.**

Procter & Gamble Hygiene and Health Care Ltd. (PGHHCL) is one of India's fastest growing FMCG companies that has in its portfolio WHISPER – India's leading Feminine Hygiene brand, and VICKS – India's No. 1 Health Care brand and Old Spice. The Company has carved a reputation for delivering high quality, value-added products to meet the needs of consumers. PGHHCL is committed to making every day in the lives of Indian consumers better through the quality of its products and the sincerity of its service. Please visit [www.pg.com](http://www.pg.com) for the latest news and in-depth information about P&G and its brands.

**For details contact:**

**Madison Public Relations:**

Malika Bhavnani +91 9820496099; [malika.bhavnani@madisonpr.in](mailto:malika.bhavnani@madisonpr.in)

## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF Procter & Gamble Hygiene and Health Care Limited

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Procter & Gamble Hygiene and Health Care Limited** ("the Company") for the Quarter ended 30<sup>th</sup> September, 2016 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For DELOITTE HASKINS & SELLS LLP  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



K. A. Katki  
Partner  
(Membership No. 038568)

MUMBAI, 3<sup>rd</sup> December, 2016